<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220308054220N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-04</date_registration>
      <primary_sponsor>Public sector medical college Rawalpindi Pakistan</primary_sponsor>
      <public_title>USE OF PARACETAMOL AS LABOUR ANALGESIC</public_title>
      <acronym></acronym>
      <scientific_title>EFFICACY OF PARENTERAL ACETAMINOPHEN AS INTRAPARTUM ANALGESIC</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62380</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done by simple randomization. Unit of randomization will be individuals. Tool that will be used in randomization will be computer generated codes. The random sequence of these codes will be built by computer software. The allocation concealment will also be done, Blinding description: Participants, Health care provider, Person doing intervention, Data collector, Outcome assessor all will be blind. principle investigator, Manuscript writer, Data safety and monitoring board will not be blind. Vial of placebo and paracetamol both will have computer generated code, which will only be decoded by principal investigator.</study_design>
      <phase>3</phase>
      <hc_freetext>Labour pain.</hc_freetext>
      <i_freetext>Intervention 1: Control group:In this group placebo, normal saline will be given intravenous to pregnant lady in active labour stage with 3-4 cm cervical dilation and main primary outcomes that is pain is measured at 15 min, 30 min, 1 hour, 2,3,4 hour will be measured. Other primary outcomes are BMI measured by calculating weight by weight machine, pulse meaured by HRM and blood pressure measured by sphygmomanometer before and after giving the dose. Repeat the dose after 4 hour. And again measure the pain , pulse and blood pressure following same pattren of time as for first dose. Pain will measured by VAS ( visual.anslogue scale). Normal saline is 0.9% NaCl. It is 0.9grams of NaCl in 100 ml of water.Dose is 100 ml of normal saline. Secondary outcomes that are duration of labour, Apgar score measured by Apgar scale, complications during delivery will be assessed by person measuring outcomes, side effects after giving dose will be measured by outcome assessor. Intervention 2: Intervention group: In this group, acetaminophen be given intravenous to pregnant lady in active labour stage with 3-4 cm cervical dilation and main primary outcomes that is pain is measured at 15 min, 30 min, 1 hour, 2,3,4 hour will be measured. Other primary outcomes are BMI measured by calculating weight by weight machine, pulse meaured by HRM and blood pressure measured by sphygmomanometer before and after giving the dose. Repeat the dose after 4 hour. And again measure the pain , pulse and blood pressure following same pattren of time as for first dose. Pain will measured by VAS ( visual.anslogue scale). Both Doses will be same i.e; 1000 mg of acetaminophenin 100ml of normal saline. Secondary outcomes that are duration of labour, Apgar score measured by Apgar scale, complications during delivery will be assessed by person measuring outcomes, side effects after giving dose will be measured by outcome assessor.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
title: Results. Tables and graphs of primary outcome and secondary outcome will be shared.

When:
it will be given in the duration of 10 months to 36 months after publishing. It will be available lifelong

To whom:
everyone

Conditions:
everyone who want to take advantage of this trial results will be allowed for the service of humanity.

Where to obtain:
they can talk to principal investigator of this trial Wajeha Najeeb. E-mail: wajeha.najeeb@hotmail.com

How to obtain:
email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Wajeha najeeb</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Abid majeed road Rawalpindi Pakistan</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>46000</zip>
        <telephone>+92 333 0335060</telephone>
        <email>wajeha.najeeb@hotmail.com</email>
        <affiliation>Public sector medical college Rawalpindi Pakistan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Wajeha najeeb</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Abid majeed road Rawalpindi Pakistan</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>46000</zip>
        <telephone>+92 333 0335060</telephone>
        <email>wajeha.najeeb@hotmail.com</email>
        <affiliation>Public sector medical college Rawalpindi Pakistan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primigravida of 18–35 year.
Full-term with uncomplicated spontaneous onset of labour at term (37–42 weeks gestation).
Singleton pregnancy.
Cervical dilatation of 3-5 cm.
Cephalic presentation of fetus.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Malpresentation of fetus.
Multiparous women.
Previously scarred uterus (post myomectomy, post cesarean).
Preterm labour.
Antepartum hemorrhage.
History of drug allergy or hypersensitivity.
Fetal distress (abnormal foetal monitoring during labour).
Intrauterine foetal death.
Refusal by parturient.
History of alcohol/drug abuse.
Systemic and local sepsis.
Deranged coagulation profile.
Obstetric complications (e.g., premature rupture of amniotic membranes).
Women with clinical evidence of cephalopelvic disproportion.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>080.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group:In this group placebo, normal saline will be given intravenous to pregnant lady in active labour stage with 3-4 cm cervical dilation and main primary outcomes that is pain is measured at 15 min, 30 min, 1 hour, 2,3,4 hour will be measured. Other primary outcomes are BMI measured by calculating weight by weight machine, pulse meaured by HRM and blood pressure measured by sphygmomanometer before and after giving the dose. Repeat the dose after 4 hour. And again measure the pain , pulse and blood pressure following same pattren of time as for first dose. Pain will measured by VAS ( visual.anslogue scale). Normal saline is 0.9% NaCl. It is 0.9grams of NaCl in 100 ml of water.Dose is 100 ml of normal saline. Secondary outcomes that are duration of labour, Apgar score measured by Apgar scale, complications during delivery will be assessed by person measuring outcomes, side effects after giving dose will be measured by outcome assessor.</i_keyword>
      <i_keyword>Intervention group: In this group, acetaminophen be given intravenous to pregnant lady in active labour stage with 3-4 cm cervical dilation and main primary outcomes that is pain is measured at 15 min, 30 min, 1 hour, 2,3,4 hour will be measured. Other primary outcomes are BMI measured by calculating weight by weight machine, pulse meaured by HRM and blood pressure measured by sphygmomanometer before and after giving the dose. Repeat the dose after 4 hour. And again measure the pain , pulse and blood pressure following same pattren of time as for first dose. Pain will measured by VAS ( visual.anslogue scale). Both Doses will be same i.e; 1000 mg of acetaminophenin 100ml of normal saline. Secondary outcomes that are duration of labour, Apgar score measured by Apgar scale, complications during delivery will be assessed by person measuring outcomes, side effects after giving dose will be measured by outcome assessor.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain assessment. Timepoint: After first dose of paracetamol in Group A and placebo in Group B administration pain will be measured at 15 minutes, 30 minutes, and then at hourly intervals till 4 hours and then readminister the second dose of paracetamol and placebo and then will measure outcome at 15 minutes, 30 minutes, and then at hourly intervals till 4 hours. Method of measurement: Visual Analogue Scale to measure pain.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: At the start of intervention. Method of measurement: Weight by weighing machine in kgs and height in feet by scale.</prim_outcome>
      <prim_outcome>Pulse rate. Timepoint: Before intervention and one time in middle of 4 hours after intervention of first dose and second dose. Method of measurement: Heart rate monitor (HRM).</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: Before intervention and one time in middle of 4 hours after intervention of first dose and second dose. Method of measurement: Sphygmomonometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of labour. Timepoint: Duration of first stage of labour, duration of second stage, total duration of labour. Method of measurement: Clock to measure time of first and second stage of labour and total duration of labour.</sec_outcome>
      <sec_outcome>Complications during delivery. Timepoint: During three stages of labour. Method of measurement: Health care provider will measure using clinical findings.</sec_outcome>
      <sec_outcome>Side-effects after intervention: Nausea, vomiting, sedation, dizziness. Timepoint: During three stages of labour. Method of measurement: Health care provider will measure using clinical findings.</sec_outcome>
      <sec_outcome>APGAR. Timepoint: At 1 min and 5 min. Method of measurement: APGAR scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Public sector medical college Rawalpindi Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-17</approval_date>
        <contact_name>Ethical review committee of Public sector Medical college</contact_name>
        <contact_address>Abid Majeed Road Rawalpindi Cantt Rawalpindi Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
